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Abstract 
A 70-year-old man was admitted to our hospital for evaluation of a rapidly progressive 
erythrodermia. He had superficial lymph node swelling and gluteal/inguinal nodosum-like 
lesions. A skin biopsy of the erythrodermia showed dense mixed infiltrates distributed 
throughout the whole dermis, predominantly consisting of small lymphocytes and 
histiocytes with multinucleated giant cells presenting with a granulomatous appearance. The 
dense infiltrates showed a characteristic angiocentric pattern surrounding the upward 
vasculature interconnecting the subcutaneous/subpapillary plexus in the dermis. Some 
infiltrating lymphocytes showed mild atypia with somewhat irregularly shaped nuclei. Their 
immunologic staining profiles supported the diagnosis of lymphomatoid granulomatosis. 
Despite the dense angiocentric infiltration in the dermis, typical angiodestructive infiltration 
with necrotic changes was not seen on pathological examination. In this case, in situ 
hybridization yielded negative findings for Epstein-Barr virus-encoded RNAs. Three months 
after the onset of erythrodermia, the patient developed pulmonary lymphomatoid 
granulomatosis. Corticosteroid pulse therapy was effective for the treatment of severe 
pulmonary infiltrations and erythrodermia. However, there had been mild recurrence of the 
condition or hypereosinophilia during the 4 years of follow-up. Low maintenance doses of 
cyclophosphamide and corticosteroid provided the patient symptomatic relief to date. 
 
Introduction 
Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-associated 
B-cell lymphoproliferative disorder that has similar characteristics as lymphomatous 
and granulomatous diseases. The disease is pathologically classified as a large 
angiocentric and angiodestructive B-cell lymphoma that consists of small numbers of Case Rep Dermatol 2011;3:244–250 
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EBV-positive neoplastic B-cells, along with a diffuse background predominantly 
expressing reactive CD3+ and/or CD4+ T-cells. 
The lungs, liver, kidneys, and nervous system are affected most frequently. Usually, 
the skin is affected in approximately 45% of the patients [1]. Isolated cutaneous LYG 
has also been reported [2]. Patchy, occasionally painful erythematous macules, papules, 
and plaques are typically observed in the gluteal regions and in the extremities. 
Erythema may sometimes involve nodosum-like subcutaneous nodules that tend to 
ulcerate but are often limited to the trunk [3]. In this paper, we report a rare case of 
erythema that initially presented with erythrodermic skin lesions and progressed to 
pulmonary symptoms. 
Case Report 
A 70-year-old Japanese man presented with a progressively worsening cutaneous 
papuloerythematous rash on the trunk. During the initial assessment, laboratory investigations 
showed only hypereosinophilia in the peripheral blood without atypical lymphocytes. The initial skin 
biopsy revealed moderate infiltration of lymphocytes and eosinophils in the surrounding vessels of 
the superficial dermis. Because he had received indapamide (a sulfonamide-derived diuretic), 
doxazosin mesylate for hypertension, and other medications for benign prostate hypertrophy 1 year 
before the onset of the condition, drug eruption was suspected, and all his medicines were suspended. 
He was treated with topical corticosteroids. Despite the topical treatment, the papules rapidly spread 
to his entire body. He had recurring high fever and, therefore, was admitted to our hospital. No human 
T-cell leukemia virus type 1 or human immunodeficiency virus antibodies were detected in the serum. 
The serum levels of antibodies against the EBV-specific antigens were as follows: anti-viral capsid 
antigen (VCA):immunoglobulin G (IgG), 1:40; VCA:IgM, negative; VCA:IgA, negative; early antigen:IgG, 
negative; early antigen:IgA, negative; and EBV-determined nuclear antigen:IgG, 1:10. His whole-body 
CT scan showed no lymph node swellings in the neck and the thoracic and abdominal cavities. 
The second skin biopsy showed superficial and deep dense mixed infiltrates in the dermis without 
epidermal involvement. The infiltrates were angiocentric, and they predominantly consisted of small 
lymphocytes and histiocytes with multinucleated giant cells. The infiltrating lymphocytes sometimes 
showed mild atypia with slightly irregularly shaped nuclei. Their profiles were CD3+/CD5+/CD8+/ 
CD45RO+/CD4– (fig. 1). The histiocytes were CD68+. The CD20+/CD79a+ B-cells were few. Although 
angiodestruction and necrosis were absent, cellular infiltration vaguely showed a granulomatous 
appearance. In situ hybridization yielded negative findings for EBV-encoded RNAs. 
Although topical corticosteroid therapy was further continued, his cutaneous lesions continued to 
spread on to nearly his whole body. Two months after the onset, the lesions merged and took an 
erythrodermic appearance, with superficial lymph node swelling (fig. 2). Several nodular skin lesions 
were also observed in the inguinal and perineal areas. The third skin biopsy revealed a large number 
of infiltrating lymphocytes, whereas no necrosis or large lymphocytes were seen (fig. 3). The Ig 
heavy-chain or T-cell receptor beta-chain rearrangements in the skin were not detected in PCR and 
southern blot analyses. 
Three months after the onset of the condition, the patient had sustained high fever and cyanosis. 
However, he did not have cough or chest pain. His chest CT scan showed diffuse infiltrative lesions in 
the bilateral lungs and pleural effusion without nodules or lymph node swelling. Of the cells in the 
pleural effusion, 96.9% were small lymphocytes and histiocytes. The cytodiagnosis was negative for 
malignancy. His arterial blood gas examination revealed severe hypoxemia (PO2 29.9 mm Hg; PCO2 
37.4 mm Hg; pH 7.462, A-aDo2 79.1). Although a lung biopsy was not done because of severe 
hypoxemia, LYG was diagnosed on the basis of the cutaneous pathological findings and the pulmonary 
symptoms. He was treated with corticosteroid pulse therapy (methylprednisolone 1 g/day for 3 days) 
for acute respiratory distress syndrome. The steroid pulse therapy was quite effective. Soon after, his 
hypoxemia improved and the diffuse reticular shadows of the lungs disappeared on the third day of 
the pulse therapy. Furthermore, the erythrodermia and the hypereosinophilia improved with the 
intravenous corticosteroid therapy. Case Rep Dermatol 2011;3:244–250 
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In the course of the corticosteroid dosage tapering, mild hot flashes on his face, trunk, and arms 
occasionally appeared, and gradually, the number of eosinophils increased. Although 
cyclophosphamide (50 mg/day) was taken with prednisolone (12 mg/day), mild recurrence with 
several small nodular lesions in the perineal areas without erythrodermia was observed 7 months 
after the onset of the condition. However, the lesions disappeared gradually with the sustained 
therapy, and the patient has been continuously been taking prednisolone at a dose of 11 mg/day and 
cyclophosphamide at a dose of 50 mg every other day, without recurrence, for 4 years up to date. 
Discussion 
LYG was first described by Leibow et al. [1] in 1972 and was initially thought to be a 
T-cell lymphoproliferative disorder owing to the prominence of CD4+ T-cells observed 
in biopsy specimens. It was later demonstrated that LYG is an EBV-associated B-cell 
lymphoproliferative disorder, in which a large number of infiltrating T-cells are 
reactive [4–6]. 
EBV is usually detected in LYG because of the type 3 latency pattern. Therefore, 
currently LYG is considered as an EBV-related T-cell-rich monoclonal B-cell 
lymphoproliferative disorder with a broad pathological spectrum and variable 
malignant potential. Angiocentric infiltration with vasculitis and necrosis is 
pathognomonic and results from the angiodestructive potential of the polymorphous 
lymphoid infiltrate, with predominantly reactive T-lymphocytes and sparse clonal EBV-
positive B-cells.  
The dermatologic manifestations of LYG are diverse. However, most patients show 
multiple erythematous, dermal, and subcutaneous papules and nodules on the 
extremities and/or on the trunk [3, 5]. The histologic appearance of the cutaneous 
lesions correlates with the clinical pattern. Angiodestruction, necrosis, and cellular 
atypia are much more common in the deeper subcutaneous nodules. Lipford et al. [7] 
divided LYG lesions into 3 histologic grades on the basis of the degree of cytologic 
atypia in the lymphoid cells and the extent of the inflammatory background. Grade I 
lesions consist of an angiocentric and angiodestructive lymphoid proliferation without 
cytologic atypia. Necrosis is not usually observed. Grade II lesions contain occasional 
large lymphoid cells with few marked cytologic atypia. Necrosis is more commonly 
seen. Grade III lesions show marked cytologic atypia present in small and large 
lymphoid cells, which is termed angiocentric lymphomas. Necrosis is prominent. 
Previous studies [5, 6] have shown that the number of EBV-positive cells correlates 
with histologic grade. Beaty et al. [5] revealed that the plaque lesions were negative for 
EBV and demonstrated IgH polyclonal patterns. The EBV-positive lesions contained 
large cytologically atypical cells and were associated with marked necrosis. Our case 
predominantly presented erythematous plaque lesions that resulted in erythrodermia 
and a negative reaction to EBV. According to the histologic grading described above, 
our case was grade I, which corresponded to the results of the in situ hybridization for 
EBV and the PCR assay for the IgH gene. 
LYG is a lymphoproliferative disorder primarily involving the lungs. Cutaneous 
lesions appear before the onset of the pulmonary disorder in 15% of LYG cases, such as 
in our case [5]. Pulmonary lesions in LYG present a variety of radiographic features, 
from diffuse infiltrates to nodules, as well as the presence of cutaneous lesions [3, 6]. 
Although there were no pulmonary nodular lesions, our case showed severe hypoxemia Case Rep Dermatol 2011;3:244–250 
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due to diffuse infiltrates. A similar case of LYG mimicking interstitial pneumonia 
without cutaneous lesions was reported to be histological grade I and negative for EBV 
[8]. 
The immunophenotypes of the infiltrating lymphocytes in LYG previously reported 
are CD3+, CD4+/–, CD8+, CD20+, and CD79a+ [2, 5–7, 9]. In LYG, EBV is localized to CD20+ 
B-cells in the lungs and the skin [4, 10, 11]. Several reports indicate that EBV was more 
difficult to identify in skin lesions than in the lungs in LYG [4, 5]. McNiff et al. [4] 
postulated that EBV-containing B-cells are few or EBV-containing B-cells did not 
consistently home to skin, which is the reason for the difficulty in detecting LYG in the 
skin [4]. The immunohistochemical stainings of the cutaneous lesions in our case 
showed a few B-cells in the skin, which might show false-negative results for EBV. In 
addition, serological analysis revealed only the past infection, without reactivation of 
EBV. 
The mechanism by which the condition of the present case progressed to 
erythrodermia is unclear. Most erythrodermic cases of lymphoproliferative disorders 
present characteristic pathological features. However, it is often observed that the 
number of atypical cells differ greatly from specimen to specimen in the same patient. 
Abel et al. [12] found that the lymphocyte phenotypes of their patients with 
erythrodermia caused by mycosis fungoides/Sezary syndrome or benign disease were 
strikingly similar. They suggested that erythrodermic mycosis fungoides/Sezary 
syndrome skin lesions compromise a greater proportion of cells involved with host 
response than other types of mycosis fungoides. It is very likely that numerous host 
response T-cells lead to symptoms of erythrodermia. 
Macon et al. [13] revealed that the presence of interleukin (IL)-4 in T-cell-rich B-cell 
lymphomas (TCRBCLs) but not in other diffuse large B-cell lymphomas and reactive 
lymph nodes indicated that IL-4 may be a major factor involved in the pathobiology of 
TCRBCLs. In addition, several interesting studies [14, 15] suggested that IL-4 not only 
have proliferative effects on resting B-cells but also anti-proliferative effects on 
activated neoplastic B-cells. IL-4 may influence the pronounced T-cell reaction in the 
TCRBCLs and contribute to the low numbers of neoplastic B-cells. We speculate that 
some cytokines like IL-4 may cause host response by abundant production of T-cells, 
suppress proliferation of neoplastic B-cells, and advance skin lesions to erythrodermic 
features. 
A number of studies trying to find an effective way to treat LYG have been reported. 
However, a standard therapy has not yet been established, and treating LYG remains a 
challenge. The variety of symptoms and the clinical course make this condition difficult 
to diagnose and treat. Grading the disease by immunohistological examination and in 
situ hybridization is an important basis for choosing the right treatment that is 
currently available. Initial use of combination chemotherapy, such as CHOP, was 
recommended for all aggressive cases that could develop to malignant lymphoma. 
Interferon-α has been a promising therapy because LYG grades I and II without 
monoclonal B-cell population is not an autonomous malignant proliferation but rather 
an EBV-driven lymphoproliferative disorder [5]. However, in the present case, which 
was categorized as grade I and showed erythrodermia without B-cell monoclonality, 
the low maintenance doses of corticosteroid and cyclophosphamide were adequate to 
suppress the abundant activated T-cells and sustain clinical remission for a long period. Case Rep Dermatol 2011;3:244–250 
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Fig. 1. Second skin biopsy specimen. a Hematoxylin-eosin stain of the upper dermis of the 
erythrodermic skin, demonstrating dense infiltrates of small atypical lymphocytes, eosinophils, 
histiocytes, and multinuclear giant cells around vessels, with an angiocentric pattern and 
skin appendages (original magnification ×100). Granulomatous changes are also seen. 
b Immunohistochemical staining of CD8+ T-cells around small vessels in the upper dermis (original 
magnification ×40). c CD20+ B-cells sparsely located in the lesion. d In situ hybridization showing a 
negative staining result for EBV-encoded small RNA (original magnification ×100). 
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Fig. 2. The patient developed erythrodermic lesions covering the whole body. Erythematous papules 
are also seen in his upper extremities. 
 
 
 
Fig. 3. Third skin biopsy specimen. Hematoxylin-eosin stain of the whole dermis of the indurated 
erythrodermic skin of the back. Dense lymphocyte infiltrates are seen in a characteristic columnar 
angiocentric pattern, surrounding the upward vasculature interconnecting the subcutaneous/ 
subpapillary plexus (original magnification ×1.25). 
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